Coal, biotech and the Pentagon list: a single week reveals the new shape of US–China economic statecraft
Coal, biotech and the Pentagon list: a single week reveals the new shape of US–China economic statecraft
On 8 June 2026, the United States Department of Defense added BYD, Alibaba and Baidu to its rolling list of companies it judges to be operating on behalf of the Chinese military, according to a Polymarket wire carried on the same day by TechCrunch. The Pentagon had first published an updated version of the list four months earlier, then withdrew it without explanation; the reissue, with two of China's most prominent electric-vehicle and internet-platform names attached, is the most consequential signal yet that Washington's economic confrontation with Beijing is being redesigned around a tighter, more selective perimeter.
The same week, in a different register, Chinese customs data reviewed by Reuters showed coal imports in May down 8% year on year — a quiet but meaningful signal of how the world's largest buyer of thermal coal is rebalancing its energy mix. And a Reuters Breakingviews column on 9 June argued that the Pentagon is casting a dark cloud over Chinese biotech, with US officials raising national-security objections to partnerships between American firms and Chinese counterparts, including in the gene-therapy and contract-research sectors. Read together, the three stories form a single argument: economic statecraft between the two countries is shifting from broad tariff sweeps to surgical, sector-by-sector pressure on the choke points of capital, technology and energy.
The thesis here is plain. The era of across-the-board decoupling has not arrived; it has been replaced, almost without anyone naming it, by a doctrine of selective exposure — a posture in which the United States screens Chinese firms and sectors not on ideology but on the question of whether they sit on an infrastructure of strategic advantage, and adjusts the perimeter accordingly.
The Pentagon list, and what reissuing it actually means
The Pentagon's list, first created under a Trump-administration statute, is not a sanctions instrument in itself. It does not bar US persons from transacting with named firms, nor does it automatically trigger export controls. What it does is establish a presumption: that the named companies are part of China's defence-industrial base, that dual-use risk is real, and that downstream regulators — Treasury, Commerce, the CFIUS review process, and increasingly the SEC — should treat those firms with corresponding care.
TechCrunch reported on 8 June that the Pentagon's reissue added BYD, the Shenzhen-based electric-vehicle and battery manufacturer, alongside internet platforms Alibaba and Baidu, and robotics-maker Unitree. The original list had been pulled in February 2026, again without formal explanation, leaving downstream actors in a holding pattern. The reissue restores, and broadens, that presumption. The mix is telling. BYD is the world's largest EV maker by volume and a global leader in lithium-iron-phosphate battery chemistry. Alibaba and Baidu are core infrastructure of the Chinese consumer internet, with deep footprints in cloud computing and large-model AI. Unitree makes quadruped and humanoid robots — a category in which Chinese firms have moved from followers to leaders on price-performance in roughly three years.
For the US side, the analytic case is straightforward: vehicles, cloud, AI and autonomous robotics are precisely the sectors that defence planners expect to dominate the next decade of military competition, and a presumption of military-civil fusion inside Chinese industry means that commercial champions cannot be cleanly separated from state capability. For the Chinese side, the rebuttal is equally structural: that the list conflates commercial success with military intent, that the presumption is unrebuttable in practice, and that the naming of consumer-facing companies alongside defence vendors is a categorisation error that, repeated, will degrade US firms' ability to operate in China too.
The Chinese foreign-ministry line on such designations has been consistent for several years: that the United States is generalising a national-security concept, that it is using administrative lists to substitute for legal process, and that the cost will be borne by US companies that lose access to one of the world's largest consumer and capital markets. Alibaba, Baidu and BYD have not been directly quoted in international coverage of this reissue at the time of writing; their formal investor filings and HKEX/SEC disclosures in the days ahead will be the next clear data point on whether secondary listings, ADRs, or US index inclusion are affected.
Coal, biotech, capital: the sectors Washington actually has leverage in
The Pentagon list works because the US capital market is the centre of gravity for global finance. A presumption of military ties is enough to make index providers, asset managers and bank counterparties behave differently. That is leverage the US does not have in every sector, and the coal and biotech stories in the same week show both the limit and the new line of attack.
Chinese coal imports were 8% lower in May 2026 than in the same month a year earlier, according to Reuters reporting on 9 June. China remains the world's largest coal consumer and a major importer, but the trend is well established: domestic production is being rationalised, imports are being diversified away from single suppliers, and the build-out of renewables plus nuclear is gradually compressing coal's share. The structural lesson for Washington is that Beijing has, over the past four years, substantially reduced its point-of-leverage on coal markets, which removes one of the obvious tools of US pressure.
The biotech story runs the other way. The Reuters Breakingviews column on 9 June laid out how US national-security reviews of Chinese partnerships in biotech — including gene therapy and contract research — are deterring deals and complicating capital flows in both directions. Biotech is a sector in which the United States has the lead, China has the scale, and the connective tissue of capital, talent and clinical trials runs through both. A 2024 statute, the BIOSECURE Act, gave the administration a legislative backbone for these reviews; executive-branch implementation has been the real action since.
The two stories together describe a new perimeter. In sectors where China has alternatives — energy, rare-earth processing, battery raw materials, increasingly food — US leverage is constrained. In sectors where the US has the lead and China needs the partnership — biotech, advanced semiconductors, certain AI architectures, precision instruments — the leverage is real and is being used. This is not the broad tariff war of 2018–2019. It is capital-aware statecraft.
The Chinese counter-position, stated fairly
A serious reading of these moves must give the Chinese development and governance model its full weight. Over the past two decades, China has built a manufacturing base in EVs, batteries, solar, grid-scale storage and consumer electronics that competes on cost, scale and increasingly on IP. BYD is the clearest example: a company that in 2010 was a marginal automaker is now a global leader in EV volume and battery technology, with a vertical-integration model that Western OEMs are still trying to match. The Pentagon's list effectively acknowledges that success — by naming BYD alongside a defence prime, Washington is treating a commercial carmaker as strategically consequential.
On the biotech side, Chinese clinical-trial capacity and contract-research organisations have become a structural part of the global drug-development pipeline. The argument from the Chinese side — articulated in industry forums and state media commentary in recent years — is that screening Chinese biotech on national-security grounds will lengthen timelines and raise costs in the West, while accelerating the maturation of a parallel Chinese drug-development stack that will eventually compete on its own terms. That is not propaganda; it is a plausible forecast, and the capital flows in 2024 and 2025 — Chinese biotech listings in Hong Kong, US venture capital pulling back from Chinese partners, parallel CRO capacity build-outs in Shanghai and Suzhou — are consistent with it.
At the same time, the Western concern cannot be waved away. The military-civil fusion doctrine in China is a documented industrial policy with named institutional backing. The transfer risk in gene-therapy vectors, advanced fermentation, and AI-enabled drug discovery is real, even if the magnitude is debated. A serious analysis holds both: the Pentagon list overreaches by treating commercial consumer firms as defence vendors, and a tighter perimeter around genuinely dual-use biotech is justified by evidence rather than prejudice.
Selective exposure as doctrine
The pattern that emerges is what might be called selective exposure. The US is no longer trying to decouple in the abstract. It is building a perimetre: identifying the nodes — firms, sectors, capital channels — that connect to strategic advantage, and adjusting access selectively. The Pentagon list is one instrument. CFIUS review, export controls on advanced chips and lithography, the BIOSECURE Act, and Treasury's sectoral screens are others. The perimeter is being drawn, in other words, not along the line of all Chinese firms, but along the line of where Chinese commercial capability meets US national capability.
This is a different theory of economic statecraft from the one that dominated 2018–2020, when the assumption was that broad tariffs and export controls would force structural realignment. That bet did not pay off: trade volumes adjusted, third-country routing expanded, and the US agricultural and consumer-goods sectors absorbed disproportionate cost. Selective exposure is the more calibrated successor. Its premise is that, in a deeply integrated global economy, the goal is not to sever ties but to control the rate of flow along the most sensitive channels, and to use the leverage of US capital and dollar-based settlement to do the controlling.
For China, the response is also becoming more selective. The coal-import data show a rebalancing of energy supply. The continued build-out of domestic semiconductor capacity, the maturation of homegrown AI stacks, and the deepening of cross-border payment infrastructure in renminbi are all slow, sector-by-sector moves to reduce the points of US leverage. Both sides, in other words, are playing the same game on a sectoral board, and the question for investors, diplomats and operators is which sectors the perimeter will tighten around next.
Stakes and the forward view
The concrete stakes over the next 12 to 24 months sit in three places. First, capital markets. The Pentagon list and similar designations will continue to feed into index-provider reviews, ESG screening, and the diligence of US institutional asset managers; a long tail of Chinese firms that were already trading at US-vs-Hong-Kong discounts is likely to widen that discount further for names on or near the list. Second, the biotech and pharma pipeline. If US national-security review of Chinese clinical and CRO partners becomes routine rather than exceptional, drug-development timelines in the West will lengthen, and Chinese domestic capacity will continue to absorb the redirected work. Third, the diplomacy of energy. The May coal-import number is one data point; if the trend continues, the price-setting power of thermal coal will shift gradually away from the Pacific and toward India and Southeast Asia, with consequences for Australian, Indonesian and Russian exporters that depend on Chinese demand.
What remains genuinely uncertain is whether selective exposure holds as a doctrine. It requires continuous regulatory maintenance, inter-agency alignment, and a willingness to defend partial measures against political pressures to either escalate to broad bans or relax into re-engagement. The quick withdrawal of the Pentagon list in February 2026, and the unexplained reissue four months later, is itself a sign of how unsettled the perimeter still is. The 2026 mid-term environment in the US, the trajectory of EU policy on outbound investment screening, and the next round of US-China cabinet-level talks will all be tests of whether the doctrine stabilises or oscillates.
What the sources do not show, and what no one can responsibly assert at this point, is the final shape of that perimeter. The list will change; the companies named will contest designations they consider unfair; the Chinese government will press for reciprocity; and the US capital market, which is the real instrument of leverage in this doctrine, will respond in ways that no government can fully control. The next clear data points will come from quarterly disclosures by Alibaba, Baidu, BYD and Unitree, from the next CFIUS annual report, and from the next monthly customs release from Beijing. Until then, the most honest read of the week is that economic statecraft between the two countries has entered a more selective, more capital-aware phase — one in which the companies on a list matter as much as the tariffs on a schedule.
Desk note: Monexus framed the Pentagon list, the coal-import data and the biotech pressure as a single shift in economic-statecraft doctrine — selective exposure — rather than as three unrelated wires. The Chinese position on the list and on biotech screening is given equal structural weight to the US national-security case, consistent with the publication's standing approach to China coverage.
Wire provenance
This editorial synthesis draws on the following public wire/social posts:
- http://reut.rs/4uoGpuC
- http://reut.rs/43VjsnR